Ipamorelin vs Sermorelin: two different medicine histories.

The names meet at growth hormone

Ipamorelin vs sermorelin sounds like a choice between two versions of the same idea. The receptor histories tell a different story. Sermorelin mimics the body's growth-hormone-releasing hormone and acts at the GHRH receptor. Ipamorelin is a synthetic five-amino-acid peptide acting at the ghrelin receptor, GHS-R1a.

The sermorelin clinical review describes the GHRH-analog approach to growth-hormone insufficiency. The ipamorelin founding study describes a selective response in rat cells, rats and swine. I prefer that pair of descriptions to a winner-and-loser comparison: they explain what each compound was trying to accomplish before the names became alternatives in a search box.

Selectivity started with older GHRPs

Older growth-hormone-releasing peptides could raise ACTH, cortisol and prolactin alongside growth hormone. Ipamorelin's distinguishing result was avoiding ACTH and cortisol spillover in the acute animal experiments, even at more than 200 times the growth-hormone ED50. It solved a specific problem within its own peptide family.

Sermorelin acts through the GHRH pathway, which did not have that stress-axis spillover problem to begin with. I would give ipamorelin credit for its selectivity without treating that achievement as a demonstrated advantage over sermorelin in long-term human safety. There is no head-to-head clinical outcome trial here to support that leap.

One file includes an approved-drug past

Sermorelin was historically FDA-approved for diagnosing and treating growth-hormone deficiency, then withdrawn from the U.S. market for commercial reasons rather than safety. That history does not make every present-day preparation an FDA-approved product.

Ipamorelin has never had an approved drug indication. Its human volunteer pharmacokinetic study recorded an approximately 2-hour half-life after intravenous administration; its published bowel-recovery trial missed the primary endpoint. Neither compound's ability to stimulate hormone release supplies a demonstrated wellness benefit.

For me, the development histories are the most useful comparison. Former approval in a particular clinical context and selective preclinical pharmacology are different kinds of achievement. Neither can be substituted for evidence on the specific preparation and purpose now under discussion.

Sermorelin and ipamorelin: a pair remains a hypothesis

The different receptors explain why ipamorelin and sermorelin are sometimes discussed together. Studies such as hexarelin with GHRH in healthy men and GHRP-2 with GHRH in older adults support a class-level combination principle. They did not test sermorelin with ipamorelin, and no controlled human outcome trial has tested that particular pair.

The receptor distinction persuades me. It does not complete a clinical file for either this pair or CJC-1295 with ipamorelin. Both compounds are prohibited in sport under WADA. A direct human study of the pair would have to answer the questions about safety and benefit.